Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — Shareholder Meeting (May 2026)
34 slides from Vita Life Sciences's shareholder meeting presentation, May 28, 2026
Slide 1: 2026 AGM Address & Presentation announcement
28 May 2026 Market Announcements Australian Securities Exchange Ltd Level 27, 39 Martin Place, Sydney, NSW 2000 For personal use only Dear Sir/ Madam, 2026 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION The Vita Life Sciences Ltd addresses to the 2026 AGM by the Chairman and the Managing Direct
Slide 2: Chairman's Script - Welcome and Introduction
Vita Life Sciences Limited – 2026 Annual General Meeting Chairman’s Script - 28 May 2026 Welcome Good afternoon ladies and gentlemen. I’m Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today. Welcome to the VLS 2026 Annual General Meeting.
Slide 3: Meeting procedure and agenda
I would like to welcome those shareholders that are observing us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that
Slide 4: Proxies and financial statements
Shareholders observing online who have already submitted their votes by proxy should note that your votes will already be counted towards the poll. The proxies have been inspected and all those validly lodged have been accepted. Proxies have been received representing up to 36,611,514 Shares or arou
Slide 5: Remuneration Report
Remuneration Report In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows: To consider and, if thought fit, to pass, with or without amendment, Resolution 1, Adoption of the Remuneration Report for the Financial year ended 31 December 2025, as an ordinary
Slide 6: Re-election of Director and Share Buy-Back
“That Peter Osborne, a director retiring by rotation in accordance with clause 14.4 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company.” An explanation of Resolution 2 and information on Mr. Osborne is found on page 10 of the Notice of the Mee
Slide 7: Share buy-back and Long Term Incentive Plan
conditions set out in the Explanatory Statement accompanying the 2026 Annual General Notice of Meeting at which this resolution is to be put.” An explanation of Resolution 3 and information the share buy-back, is found from page 10 of the Notice of Meeting. The number of valid proxy votes that have
Slide 8: Poll procedure
The number of valid proxy votes that have been received on this motion are shown on the screen. If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A. [PAUSE AND TAKE QUESTIONS] Ladies and gentlemen, that concludes the resolutions to be voted. As ment
Slide 9: Other business and question time
AGENDA 3 OTHER BUSINESS & QUESTION TIME Is there any other business that can lawfully be brought forward? [PAUSE TO CONSIDER] If there are none, I now invite shareholders to raise their hand if there are any questions for management or the auditor, or submit it via the Q&A function. [PAUSE AND TAKE
Slide 10: Managing Director Address - AGM 2026
Managing Director Address – Annual General Meeting 2026 Good afternoon shareholders, colleagues, and partners. Thank you for joining us today for the 2026 Annual General Meeting of Vita Life Sciences. It is a pleasure to welcome you, whether you are here with us in person or joining online. Your con
Slide 11: Delivering Disciplined Growth
prior year. This marks 16 consecutive years of dividend payments and a compound annual dividend growth rate of 24% over the past six years. These results are not accidental. They are the outcome of a clear strategy, disciplined execution, and a commitment to long-term value creation. Delivering Disc
Slide 12: Retail reach, marketing and product innovation
Our products are now available in over 3,000 retailers, including some of the largest offline and online health and pharmacy partners in the region. We are proud of our global footprint, and we remain committed to expanding our presence in a disciplined and strategic manner. Marketing and Brand Inve
Slide 13: Priorities, ESG and closing remarks
• Maintaining momentum in offshore markets • Driving margin through product mix, pricing, and efficiency • Disciplined capital deployment • Pursuing accretive acquisition opportunities • Defending and growing our profitable core channels These priorities reflect our commitment to sustainable growth,
Slide 14: Annual General Meeting May 2026
For personal use only Annual General Meeting 28 May 2026
Slide 15: Managing Director - Annual General Meeting May 2026
For personal use only Managing Director- Annual General Meeting May 2026 1
Slide 16: Financial Highlights Full Year
REVENUE Financial $93.3M For personal use only Highlights PBT $14.4M UP 17.3% VS PCP Full year UP 14.1% VS PCP • Record full year performance dividend • Gross profit margin ↑ 1.7% to 61% 14CPS EQUITY $56.2M CASH • Cash conversion: strong 126% RESERVES • Strong balance sheet with no borrowings $35.6M
Slide 17: VLS Financial History
VLS Financial History For personal use only VLS Revenue & Profits (A$’000) 100,000 15,000 80,000 10,000 60,000 40,000 5,000 20,000 - - 2020 2021 2022 2023 2024 2025 Revenue Net profit after tax Profit bef tax & finance • Revenue growth of 101% over last 5 years • Compounded annual dividend growth of
Slide 18: Profitable, cash-generative healthcare business
For personal use only Profitable, cash-generative healthcare business Delivering disciplined Strong domestic growth and channel performance Margin resilience margin despite competitive resilience pressures Clear focus on profitable growth and execution Disciplined capital management and balance shee
Slide 19: Operational highlights
Operational For personal use only highlights Segment performance - Broad based growth across core markets, supported by strong performances across all major channels and positive consumer sentiment. • Australia up 8% • Malaysia & Singapore up 35% Market initiatives • Continued distribution expansion
Slide 20: Our People, Our Markets, Our Partners
Our People Our Markets Our Partners For personal use only AUSTRALIA MALAYSIA SINGAPORE OVER 350 VIETNAM INDONESIA OVER 3000 EMPLOYEES RETAILERS CHINA We have over 350 employees in the Vita Life We continue to evolve and expand our Our products are available across some of the Sciences Group across A
Slide 21: Marketing
For personal use only Marketing Our marketing investment combines global scale with a deep understanding of local audiences. We connect with millions of consumers through coordinated activity across television, digital, social, radio, outdoor, print, and in-store channels. By integrating these platf
Slide 22: Brand Positioning
For personal use only Brand Positioning VitaHealth has been a people-focussed and trusted brand for over 50 years. We continue to position VitaHealth as the brand that genuinely cares. 2024 pushed this positioning further by delivering 9 major marketing and community events, as well as, entering int
Slide 23: NPD 2025
NPD 2025 For personal use only There are currently over350 products 23 new products registered across the business. launched across Australia, Malaysia and Singapore. 9
Slide 24: Awards in Australia, Malaysia and Singapore
For personal use only Australia Malaysia TOP RANKED SUPPLIER (PHARMACY – OTC) – VOICE OF THE CUSTOMER MALAYSIAN BUSINESS OF THE YEAR – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA) ADVANTAGE REPORT 2023, 2024 & 2025 BEST HALAL PRODUCT (PLATINUM) - THE STAR OUTSTANDING BUSINESS AWARDS (SOBA) NATURAL HE
Slide 25: Strategic priorities
For personal use only Defend and grow profitable Drive margin through product Strategic core channels mix, pricing and efficiency priorities Maintain momentum in offshore markets Disciplined capital deployment Accretive acquisition opportunities 11
Slide 26: Social impact & corporate responsibility
For personal use only Social impact & corporate responsibility At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We hav
Slide 27: Thank you
Thank you slide For personal use only Thank you 13
Slide 28: Resolutions
RESOLUTIONS For personal use only 1. Remuneration Report 2. Re-election of Director – Mr Peter Osborne 3. Share buy back 4. Long Term Incentive Plan
Slide 29: Proxy-Resolution
For personal use only PROXY-RESOLUTION 1
Slide 30: Proxy-Resolution
For personal use only PROXY-RESOLUTION 2
Slide 31: Proxy-Resolution
For personal use only PROXY-RESOLUTION 3
Slide 32: Proxy-Resolution
For personal use only PROXY-RESOLUTION 4
Slide 33: Disclaimer
DISCLAIMER DISCLAIMER Thank you slide For personal use only
Slide 34: Thank you
Thank you slide For personal use only Thank you